Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis-Reference-Cited by-同舟云学术

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

Published:2012-05 Issue:5 Volume:23 Page:1130-1137
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cortes J.,Calvo V.,Ramírez-Merino N.,O'Shaughnessy J.,Brufsky A.,Robert N.,Vidal M.,Muñoz E.,Perez J.,Dawood S.,Saura C.,Di Cosimo S.,González-Martín A.,Bellet M.,Silva O.E.,Miles D.,Llombart A.,Baselga J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/5/1130/481462/mdr432.pdf

Reference27 articles.

1. The biology of VEGF and its receptors;Ferrara;Nat Med,2003

2. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy;Dvorak;J Clin Oncol,2002

3. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007

4. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer;Miles;J Clin Oncol,2010

5. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer;Gray;J Clin Oncol,2009

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural clarification of mannoglucan GSBP-2 from Ganoderma sinense and its effects on triple-negative breast cancer migration and invasion;International Journal of Biological Macromolecules;2024-06

2. Mechanism of Biosimilars for the Treatment of Cancer;Biosimilars for Cancer Treatment;2024

3. LDP alleviates TKI-induced proteinuria through reversing the expression of RelA in renal tissues;Frontiers in Medicine;2023-01-19

4. Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction;Cardiovascular Research;2022-05-31

5. Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas;Frontiers in Oncology;2022-01-03